Davis Kennedy Michele, Hamilton Megan, Muathe Donald, Wildey Aldyn, Harrington Stephen, Bittel Douglas C, Filla Michael, Stehno-Bittel Lisa
College of Biosciences, Kansas City University, Kansas City, MO, USA.
Likarda, Inc, Kansas City, MO, USA.
Orthop Res Rev. 2025 Jul 11;17:299-312. doi: 10.2147/ORR.S525292. eCollection 2025.
Multipotent Stromal Cells (MSCs) are utilized as therapeutic agents for addressing musculoskeletal conditions, including knee osteoarthritis (OA). However, major challenges in the clinical application include maintenance of the cells in the joint capsule. Hyaluronic acid (HA) is endogenous in synovial joints and commercially available as a joint lubricant. We tested the hypothesis that delivery of MSCs in HA into an OA rat knee model could improve outcomes.
Rat bone marrow MSCs were suspended in a commercially available HA paste, and cell viability measured with live/dead stains. Biomarkers for MSC chondrogenesis and osteogenesis were monitored with PCR. MSCs with or without HA were injected into the knees of OA rats and histology conducted 6 weeks later.
Suspending MSC in HA resulted in a slight reduction in viability. The gene expression profile showed an increase in MSC biomarkers for cells in HA with a decrease in osteogenic markers. Four groups of treatment (vehicle, MSCs alone, HA alone, MSCs + HA) were injected into the knees of osteoarthritic rats. Pain scores, collected weekly, showed no difference between the groups. Immunohistochemistry for inflammatory markers illustrated no obvious differences between groups. Proteoglycans, indicative of cartilage, showed a loss in the vehicle group and modest signs of cartilage with MSCs alone, but when mixed with the HA, any benefit was lost. OARSI Histological Scoring completed by 2 independent technicians concluded no improvement in joint integrity with the addition of HA.
A commercially available HA failed to enhance joint regeneration compared to MSCs alone.
多能间充质干细胞(MSCs)被用作治疗肌肉骨骼疾病的药物,包括膝关节骨关节炎(OA)。然而,临床应用中的主要挑战包括在关节囊中维持细胞活性。透明质酸(HA)是滑膜关节中的内源性物质,可作为市售的关节润滑剂。我们测试了以下假设:将MSCs与HA一起递送至OA大鼠膝关节模型中可改善治疗效果。
将大鼠骨髓间充质干细胞悬浮于市售的HA糊剂中,并用活/死染色法测量细胞活力。用聚合酶链反应监测MSCs软骨生成和成骨的生物标志物。将有或没有HA的MSCs注射到OA大鼠的膝关节中,并在6周后进行组织学检查。
将MSCs悬浮于HA中导致活力略有降低。基因表达谱显示,HA中细胞的MSCs生物标志物增加,而成骨标志物减少。将四组治疗方法(赋形剂、单独的MSCs、单独的HA、MSCs + HA)注射到骨关节炎大鼠的膝关节中。每周收集的疼痛评分显示各组之间没有差异。炎症标志物的免疫组织化学显示各组之间没有明显差异。指示软骨的蛋白聚糖在赋形剂组中减少,单独使用MSCs时有适度的软骨迹象,但与HA混合时,任何益处都消失了。由2名独立技术人员完成的OARSI组织学评分得出结论,添加HA后关节完整性没有改善。
与单独使用MSCs相比,市售的HA未能增强关节再生。